Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time.

Conference Call & Webcast Details:
Date: Wednesday, March 4, 2026
Time: 8:30 am Eastern Time
Toll Free: 1-800-717-1738
Conference ID:
Webcast:
08197
Click HERE


A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugateâ„¢ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments that deliver improved efficacy and better safety.

The company's product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope) for the treatment of hematologic and solid tumor cancers such as Waldenstrom's macroglobulinemia (WM) and pediatric high grade gliomas; CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeting solid tumors, such as triple negative breast, lung and colorectal cancers; CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors with significant unmet need, such as pancreatic cancer; and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory WM and multiple myeloma (MM), non-Hodgkin's lymphomas and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough Therapy, six Orphan Drug, five Rare Pediatric Drug and two Fast Track Designations for various cancer indications. The European Medicines Agency (EMA) has also granted iopofosine I 131 PRIME and orphan drug designations for the treatment of WM.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's social media channels: X, LinkedIn, and Facebook.

Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CLRB
The Conversation (0)
Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.

Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.

Michael Gentile announces that he has filed an early warning report (the "Report") announcing the acquisition (the "Acquisition") of an aggregate of 6,840,476 common shares (each, a "Common Share") in the capital of Cascadia Minerals Ltd. (the "Company") in connection with the exercise of an... Keep Reading...
Los Andes Copper Announces Grant of DSUs

Los Andes Copper Announces Grant of DSUs

Los Andes Copper Ltd. (TSXV: LA,OTC:LSANF) (OTCQX: LSANF) ("Los Andes" or the "Company") announces that the Company has granted an aggregate of 1,944 deferred share units ("DSUs") to two directors of the Company, pursuant to the Company's deferred share unit plan (the "DSU Plan").Each DSU... Keep Reading...
Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

(TheNewswire) Muskoka, Ontario November 19th, 2026 TheNewswire Steadright Critical Minerals Inc. (CSE: SCM) ("Steadright" or the "Company") is pleased to announce that it has entered into a Share Acquisition Facilitation and Funding Agreement dated November 13, 2026 (the "Agreement") with... Keep Reading...
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Assay-confirmed shallow mineralization; Sulphide-bearing mafic rocks at depth; Spring 2027 drilling planned Ni-Co Energy Inc. (TSXV: NICE,OTC:NICLF) ("Ni-Co" or the "Company") reports results from the initial phase of its 2026 diamond drilling campaign at its 100%-owned Kremer... Keep Reading...
Metalsource Mining Inc.    Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Metalsource Mining Inc. Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Via MiningNewsWire — Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) today announces its placement in an editorial published by via MiningNewsWire ("MNW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a... Keep Reading...
Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Eric Sprott now holds approximately 19.9% of outstanding shares, as proceeds strengthen Metalsource's treasury to advance aggressive expansion drilling and larger stepouts investigating the potential scale of the Silver Hill polymetallic system in North Carolina.Metalsource Mining Inc. (CSE:... Keep Reading...

Interactive Chart

Latest Press Releases

Related News